logo
Chicken fettuccine Alfredo products voluntarily recalled over listeria concerns

Chicken fettuccine Alfredo products voluntarily recalled over listeria concerns

Yahoo6 hours ago

Ready-to-eat grilled chicken fettuccine Alfredo products that were sold at Walmart and Kroger have been voluntarily recalled due to possible listeria contamination, the U.S. Department of Agriculture's Food Safety and Inspection Service announced Tuesday.
Food manufacturer FreshRealm's establishments in San Clemente, California; Montezuma, Georgia; and Indianapolis, Indiana, are voluntary recalling the prepared pasta dishes because they "may be adulterated with an outbreak strain of Listeria monocytogenes," the FSIS stated.
The recalled products may be linked to a multistate outbreak of listeria infections across 13 states that has sickened 17 people and resulted in at least three deaths in Illinois, Michigan and Texas as of this week, according to the Centers for Disease Control and Prevention. One "pregnancy associated illness resulted in a fetal loss," the agency said Wednesday.
Three products are affected by the recall.
According to FreshRealm, the meals were sold nationwide "at Walmart, under the Marketside brand and Kroger, under the Home Chef brand."
The affected products include:
32.8-ounce tray packages containing "MARKETSIDE GRILLED CHICKEN ALFREDO WITH FETTUCCINE Tender Pasta with Creamy Alfredo Sauce, White Meat Chicken and Shaved Parmesan Cheese," with best-by dates of June 27, 2025, or prior.
12.3-ounce tray packages containing "MARKETSIDE GRILLED CHICKEN ALFREDO WITH FETTUCCINE Tender Pasta with Creamy Alfredo Sauce, White Meat Chicken, Broccoli and Shaved Parmesan Cheese," with best-by dates of June 26, 2025, or prior.
12.5-ounce tray packages containing "HOME CHEF Heat & Eat Chicken Fettuccine Alfredo with pasta, grilled white meat chicken, and Parmesan cheese," with best-by dates of June 19, 2025, or prior.
The products have a USDA mark of inspection on the label, as well as establishment numbers EST. P-50784, EST. P-47770 or EST. P-47718 printed on the side of the packaging, the FSIS said this week.
"FreshRealm has notified Walmart and Kroger to remove this meal from their shelves and inventory. Consumers who have purchased the meal should destroy it or return it to the place of purchase for a refund," FreshRealm stated in a press release Wednesday, adding that the company "remains committed to the highest standards of food safety" and is "working closely" with the Food and Drug Administration, FSIS and CDC "to provide full transparency and access throughout the process."
The recall does not apply to any other FreshRealm products, the company said.
Consumers with questions about the recall can contact FreshRealm customer service at (888) 244-1562.
The outbreak strain of listeria was identified in samples collected from sick individuals between Aug. 1, 2024, and May 27, 2025.
State and local public health officials interviewed 11 people about the foods they consumed in the month before they got sick, and seven reported eating pre-cooked meals, with four stating specifically that they had eaten chicken fettucine Alfredo products.
The outbreak strain of listeria was isolated from a routine chicken fettuccine Alfredo sample collected by FSIS in a FreshRealm establishment in March 2025. The agency noted that "the lot of chicken fettuccine alfredo represented by this sample was held during sampling, destroyed, and never entered commerce," and "subsequent investigations at the establishment that produced this product, and into the product ingredients, have not identified the source of contamination."
In its press release Wednesday, FreshRealm stated that it "has not received any direct reports of illness associated with the product and has received information on cases from the regulatory agencies, including that four consumers have reported eating the chicken alfredo product."
"The recalled product has not been established as a cause of any of these cases," the company said.
Of the 17 people sickened by the outbreak strain of listeria, 16 were hospitalized.
According to the CDC, the "true number of sick people in this outbreak is likely higher than the number reported," and the outbreak "may not have been limited to the states with known illnesses ... because some people recover without medical care and are not tested for Listeria."
"In addition, recent illnesses may not yet be reported as it usually takes 3 to 4 weeks to determine if a sick person is part of an outbreak," the CDC stated.
Listeria is a bacteria that when ingested can cause an infection known as listeriosis, according to the CDC.
The condition is most dangerous for pregnant people, newborns, people with weakened immune systems and adults 65 or older, the agency said. For people who are pregnant, being infected by listeria can cause pregnancy loss or premature birth.
According to the CDC, an estimated 1,600 people get listeriosis annually in the U.S. and about 260 people die from it.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead's twice-yearly HIV prevention injection gets FDA approval
Gilead's twice-yearly HIV prevention injection gets FDA approval

Yahoo

time25 minutes ago

  • Yahoo

Gilead's twice-yearly HIV prevention injection gets FDA approval

The US Food and Drug Administration has approved Gilead's (GILD) new HIV prevention drug. The drug, lenacapavir, only requires an injection every 6 months. Yahoo Finance Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. What's a big milestone for Gilead Sciences today. The Biotech Giant securing FDA approval for its latest HIV treatment. It's a significant step forward for that company and patients. Gilead also seeing a boost on that news. Our senior health reporter Anjali kamlani joins us now. Au, what is what is the big takeaway for for investors watching all this? Yeah, I think the big takeaway here is that investors have actually been waiting for this approval. They anticipate quick uptake and a high volume of uptake of this drug used as a pre-exposure prophylaxis, you know, prep as the common acronym for those types of drugs. Now, Gilead already has discovy for that, but the difference here is that this new use or new approval for Lenca Paviar, it is a twice yearly injectable. And that is the difference between the regular oral and this new approval. And so that is really going to help boost Gilead's revenues for the year. We know that already Lenca Paviar brings in about $60 million for the company, and they're anticipating that that will get boosted to about $150 to $195 million in revenue for the company for the year. That's the estimate that analysts are expecting with the approval, and they've been waiting for this approval for quite some time. So really good news. You can see that, you know, the stock is benefiting from this right now and is supposed to be a game changer for those patients. There are some questions about whether or not being a twice yearly drug, it will be more expensive than say a daily oral. And so that is something that Gilead has tried to addressing that they plan to have a insurance and non-insurance access point for patients as well. Thanks so much for joining us on this. Appreciate it. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

The New Wave of Women's Wearables: What's Next for the Popular Devices
The New Wave of Women's Wearables: What's Next for the Popular Devices

Yahoo

time37 minutes ago

  • Yahoo

The New Wave of Women's Wearables: What's Next for the Popular Devices

Over the past few years, women's wearables have gained popularity as women of all ages have become increasingly concerned with their health metrics. These devices are the best known for tracking your steps, heart rate, rest and more—all from your wrist or finger. Recently, the Oura Ring made its way into the space with its innovative technology that tracks health even closer than traditional devices like Fitbits and Apple Watches. But what's next for these devices? More from Flow Space Why Brooke Burke Says Menopause Is 'the Best Decade of My Life' At the 2025 Orrick-Near Future HealthTech Summit held earlier this month, a panel of tech experts discussed the innovations happening with electronic fitness devices and touched on whether these tools should be FDA-approved and reimbursed. The panel included Amy Gaston, vice president of strategic growth at OhmBody; Monica Plath, founder and CEO of Littlebird; Keara Sauber, chief strategy officer at Incora Health; Shaina Lawler, managing partner of Tippetting Capital; and moderator Georgia Ravitz, FDA & Healthcare Regulatory partner at Orrick, Herrington & Sutcliffe LLP. Ahead, the panel discusses new innovations in the wearable space plus what to expect in the future. 'You know, what's interesting about wearables?' Ravitz asked. 'It's that many of them lie at the crossroads of lifestyle products and medical devices.' Many new devices aim to go beyond tracking your steps and heat rate, and now they can help you monitor your menstrual cycle, manage opiate withdrawal and more. Although wearables are not heavily regulated, many still require labeling as 'wellness devices,' according to Gaston. At OhmBody, there is an in-house clinical team, and an in-house RMD team 'that will continue to do research and run down the pathway around endometriosis, PCOS, postpartum hemorrhaging, adolescent HMB, the list for bleeding is just so long,' Gaston shared. That's why 'we want FDA approval for indications in those spaces.' Many approved FDA devices require reimbursement to be covered by insurance, and Gaston noted that they did not want to create further barriers for women to access help today, meaning that their innovative devices must be included as wellness devices. 'We always want to be over the counter and never want to put a prescription onto our device, because it's already hard for women to get the access to care that they need. It is almost impossible for some in low socioeconomic scenarios, people who just like can't get to their doctor, etc.' Gaston explained. 'So why would we want to further that? And so, OhmBody really exists to help bridge the gap and try to close the accessibility gaps there that are happening in the awareness space.' Lawler shared that a significant challenge investors run into in the wearables space is the issue of reimbursement. 'That is a big one, especially if you're trying to work with providers,' Lawler said. 'You know, FDA clearance is something that provides a lot of comfort to providers. Not only that, your data is secure, but it's accurate and it's going to be helpful in terms of what they provide in terms of support to their patients.' Another issue is the cost of new wearable devices. If the tools were to be reimbursed, a threshold would need to be established. Most of these wearables cost over $750, and the panel noticed that people were backing away from purchasing them. That's why creating an accessible point of view is key and on the radar of most wearables device companies looking toward the future.

Healthy Interactions Expands Primary Care Alliance to Improve Cardiometabolic Care
Healthy Interactions Expands Primary Care Alliance to Improve Cardiometabolic Care

Yahoo

time41 minutes ago

  • Yahoo

Healthy Interactions Expands Primary Care Alliance to Improve Cardiometabolic Care

JACKSON HOLE, Wyo., June 18, 2025 /PRNewswire/ -- Healthy Interactions LLC, a global leader in experiential education for healthcare professionals and patients with cardiometabolic diseases, is accelerating its efforts to transform primary care with the expansion of the Healthy Interactions Primary Care Alliance. This Healthy Interactions Primary Care Alliance aims to enhance standards of care and clinical outcomes for patients with cardiometabolic conditions, with a particular focus on obesity. Through innovative Practice and Patient Obesity Virtual Conversation Map® programs, plus AI—the Alliance supports both healthcare professional and patient education. Currently, over 2,000 forward-thinking primary care practices have joined the Alliance, unified by a commitment to improving diagnosis, treatment adherence, and outcomes. Today, Healthy Interactions is pleased to announce that VillageMD, a national leader in value-based primary care, will join the Alliance and adopt Healthy Interactions' educational programs across hundreds of its practices nationwide. This collaboration represents a strategic opportunity for both organizations to advance their shared mission of improving care for patients with cardiometabolic conditions across America. "We are thrilled to build on our global success in improving care and outcomes for millions of patients with diabetes by expanding our obesity education programs for both primary care practices and patients," said Paul Lasiuk, CEO & Co-founder of Healthy Interactions. "Together, VillageMD and Healthy Interactions aim to improve diagnosis rates, increase care plan adherence, and drive better outcomes for people living with obesity." About Healthy InteractionsHealthy Interactions LLC is a global leader in experiential education programs focused on cardiometabolic health. The organization is known for its Conversation Map® platform, which blends visual learning with Socratic dialogue to engage patients meaningfully. In addition to its in-person and virtual education tools, Healthy Interactions is also expanding its impact through the development of AI-powered platforms designed to support healthcare professionals and patients in managing chronic conditions more effectively. With a presence in 129 countries and over 50 million lives impacted, Healthy Interactions continues to raise the bar in both healthcare professional and patient education. To learn more, please visit Media Contact:Shelly LeonardEmail: Sleonard@ Executive Contact:Paul LasiukCEO & Co-founder, Healthy InteractionsEmail: paullasiuk@ View original content: SOURCE Healthy Interactions, Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store